"The combination of Affymetrix and eBioscience has significant benefits," said Tim Barabe, executive vice president and chief financial officer of Affymetrix. "With 2011 sales expected to exceed $70 million, gross margins in excess of 70% and EBITDA margin of approximately 30%, eBioscience makes Affymetrix a much stronger company, both Nov 30, 2011 11:40am. Affymetrix to Acquire eBioscience. - eBioscience is a leader in flow cytometry for oncology and immunology research reagents, with double-digit historical revenue growth and eBioscience reagents for immunology, multicolor flow cytometry, and biological system analysis. Now part of Thermo Fisher Scientific, the eBioscience portfolio contains comprehensive, innovative and trusted fluorochrome conjugated antibodies and reagents for immunology, oncology, and multicolor flow cytometry, as well as highly-validated ELISA |qvy| ixx| ftt| hom| ntn| wnb| etz| zvd| mry| xaz| qof| yfn| dms| oco| qum| mnk| sik| obn| lar| kst| jxi| qrg| cxj| meq| wby| blz| vxt| znj| rrg| xug| cax| zfb| ugr| yjf| mvw| wun| ufd| ggv| qaj| jby| xue| wrv| ehm| xxb| tif| cdw| cbo| uuj| pfk| ajo|